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ABSTRACT
Leptin is a pleiotropic hormone primarily secreted by white adipose tissue. Although
originally found to regulate food intake and energy expenditure, it is now known to also
significantly affect the immune system. In this study we assessed the effect of leptin on bone
marrow derived dendritic cell (BM-DC) cytoskeletal structure and functionality.

Our

preliminary data demonstrates that the addition of physiological concentrations of exogenous
leptin to BM-DC causes cytoskeletal rearrangement specifically that of actin as evidenced by
increased number of llamelopodia/dendrites and increased staining for actin within the
llamelopodia/dendrite region. This suggests that leptin is a necessary component of DC – T cell
interaction in that leptin may be responsible for enhanced migration of the DC to draining lymph
nodes and potentiating the extent of the physical contact between these cells. We therefore
hypothesized that leptin increases the number and length of dendrites in DCs by causing a rearrangement of the cytoskeleton, specifically actin, which in turn leads to an increased capacity
to migrate and to activate T cells. To test this hypothesis we used BM-DCs from C57Bl/6 (B6)
mice enriched by magnetic bead cell sorting. The effect of leptin on BM-DC cytoskeletal rearrangement was assessed by light and confocal microscopy; actin polymerization was
determined by Western blot analysis for cell content of F-actin versus G-actin in fractioned
cellular lysates of treated cells. The functional effects of leptin on BM-DC were evaluated invitro by assessing DC migration and DC ability to active antigen-specific T cells. The
differentially treated BM-DC were evaluated in transwell migration assays to assess their ability
to migrate towards a DC-specific chemokine CCL19. Finally, treated BM-DC ability to activate
T cells was assessed in-vitro by measuring activation of an antigen-specific T cell hybridoma or
of antigen-specific primary T cells (both specific to ovalbumin) as a function of IL-2 and INF-γ
v

production or proliferation, respectively. We found that there is only a slight increase in actin
content within the cell post treatment of leptin, however this increase is not significant. The
addition of an exogenous physiological concentration of leptin to BM-DC enhanced
polymerization of actin and therefore the formation of dendrites, both in number and length and
thickness. This effect was particularly evident in the leptin and LPS duo treatment. Functionally
the presence of leptin appears to enhance migration and promote T cell activation. This is likely
due to the increased surface area, as well as dendrite number length and thickness which increase
the likelihood of DC-T cell interactions, therefore potentiating the extent of the physical contact
between these cells. This is further supported by enhanced T cell activation by leptin and LPS
treated cells as measured by incorporation of tritiated thymidine, IL-2 and INF-γ production. The
data obtained from this study suggest leptin plays an important role in immunological responses,
and may specifically contribute to the pro-inflammatory state and increased susceptibility of
autoimmune disorders found in obesity.

vi
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CHAPTER 1

INTRODUCTION

Obesity
Obesity is of immense concern for today’s health care system. Webster’s Dictionary
defines obesity as “a condition characterized by the excessive accumulation and storage of fat in
the body” (Webster’s Dictionary 2009). The cause for obesity is a greater caloric intake than that
required for an individual’s day to day activities. The World Health Organization (WHO 2006)
marks a clear difference between overweight and obesity status in adults. Overweight individuals
are identified as having a body mass index [(BMI) measured Kilograms/meter2] of equal to or
greater than 25, while obese individuals have a body mass index of 30 or higher. It appears that
these limits are not set in stone; recent studies by Dr. Chizuru Nishida (Nishida 2004) have
raised concerns due to an increase in risk of chronic obesity-related disease that has been noted
in individuals with BMIs as low as 21(Nishida 2004).
Initially, this increasing health concern primarily affected developed nations; but recent
evidence has demonstrated that this condition is predominant in urban settings of all nations
regardless of economic status (WHO 2006, Low 2009). In 2005, the World Health Organization
revealed that world-wide approximately 1.6 billion individuals over the age of fifteen were
overweight; and over 65% of the US population is overweight. Furthermore 400 million adults
world wide have been diagnosed as obese, this includes 35% of the US population. Even more
staggering, 20 million children under the age of five were declared obese in 2005 (WHO 2006,
Low 2009). As time passes these numbers are expected to continue rising.
1

Obesity is affected by factors such as metabolic status, food intake, and energy
expenditure (Freidman 1998, Matarese 2000). It carries with it a large array of risk factors and all
organ systems within an organism are highly affected by excess body mass. One critical aspect
of the body negatively affected by obesity is the immune system. Obesity can lead to
pathological conditions such as, diabetes mellitus (type II), cardiovascular diseases and even
some cancers (WHO 2006). High amounts of leptin cause blood to become highly viscous and
therefore increase likelihood for strokes, aneurisms and heart attacks. Circulatory problems kill
over 17 million people a year making them the number one killer for adults (WHO 2006).
Diabetes (type II) was recently declared world wide epidemic. It has been linked to obesity and
is expected to grow up to 50% from 2000 to 2010. Furthermore autoimmune and inflammatory
diseases such as rheumatoid arthritis, and colitis, have been found to be more prevalent in
patients with high circulating leptin levels. This is significant since obesity continues to be on the
rise. It is estimated that 700 million adults will be obese by 2015.
Obesity is not typically diagnosed suddenly since weight gain is usually gradual. Some
individuals will struggle with weight gain and loss throughout life, exponentiating the degree of
difficulty in treating this disease and those it is associated with. Obesity related conditions may
be manageable, studies have demonstrated a decrease in symptoms when leptin levels are
lowered by fasting (Fraser 1999, Bernotiene 2004, Otero 2005). Combinations of the conditions
in addition to obesity may be deadly, but luckily obesity effects are reversible by simply altering
lifestyle ensuring to increase energy output and decrease food intake. However, there are a
variety of factors that contribute to body composition including environmental and genetic
characteristics. To add to the complexity of obesity is the various adipokines that are produced
by the resulting adipose tissue that is in turn affected by the very same products (Tilg 2006,
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Moschen 2006). Fat/lipid was recently controversially categorized in the endocrine system since
it produces and secrets hormones that function locally and over long distances. There are a
variety of hormones with varying functions that are secreted by fat cells, they include but are not
limited to adiponectin, resistin, and leptin (Tilg 2006, Moschen 2006).

Leptin
Leptin is a hormone product of the OB gene found on human chromosome 7 and mouse
chromosome 6. Although leptin is produced by the placenta, gastric mucosa, bone marrow,
mammary epithelium, skeletal muscle, pituitary, hypothalamus and bones in small quantities, it
is primarily produced by the white adipose tissue and is secreted in direct correlation with the
content of adipose tissue (Friedman 1998, Frühbeck 2001). It is mainly found circulating in the
blood, either bound to serum or freely circulating. Protein bound leptin may increase in function
because of its superior ability to bind to its corresponding ligand (Sinha 1996). Concentrations of
leptin vary by individual based on metabolic and nutritional state, but higher concentrations of
freely circulating leptin have been observed in obese individuals (Maffei 1995). The average
human leptin concentration ranges from 5 ng/ml in lean individuals to 200 ng/ml in obese
individuals (Sinha 1996 and Peltz 2007). In 1997 Halas et al demonstrated that obesity produces
consistently elevated leptin serum levels. He also established an association between obesity and
leptin resistance (a decrease in leptin sensitivity) (Halas 1997). Leptin resistance is described as
having high circulating serum leptin levels but low leptin effects (Maffei 1995, Banks 2004).
One very common side effect to leptin resistance is hyperphagia, which results an increase in
body size/weight gain (Maffei 1995, Banks 2004). Additionally leptin resistance causes a
decrease in blood insulin levels and produces a pro-inflammatory environment.
The hormone leptin has many similarities with cytokines, it is therefore known as an
3

adipokine. This adipokine is a 16 kDA protein; structurally it resembles the long-chain helical
class I cytokine family, but folds like the short helix cytokine family (Madej 1995). It is the
product of the ob gene found by Zhang and Friedman in 1994. Leptin recognizes and ligates to
the OB-R receptor (Madej 1995). This receptor resembles those of the class I cytokine family
and has six different isoforms (Madej 1995). These isoforms are the product of alternative
mRNA splicing of the db gene (Ghilardi, 1994, Baumann 1996 Wang 1996, Bendinelli 2000)
and are short, long or secreted. Short receptor isoforms OB-Ra, OB-Rc, OB-Rd, and OB-Rf
contain 30-40 cytoplasmic amino acids (aa) (Wang 1996). All short isoforms mentioned are
thought to be capable of producing intracellular signaling threw the MAPK pathway. The long
isoform OB-Rb contains an intracellular domain of 300 aa with the necessary motifs to activate
the intercellular JAK/STAT pathway (Wang 1996). Diagram 1.1 illustrates the six different
receptor isoforms described above.
The MAPK signaling pathway may be used by leptin for signaling, although, the major
signaling pathways used is the Janus kinases 2 (JAK2) and signal transducers and activators of
transcription 3 (STAT3) (Frühbeck 2006, Lago 2008, Robertson 2008). Initially circulating
leptin recognizes and binds to the leptin receptor on the cells surface causing a homodimer to
form. This homodimerization of the two receptors leads to phosphorylation that causes
conformational changes. The conformational change reveals the cytosolic domain of the
receptor, this activates the JAK2 pathway which undergoes autophsophorylation and continues to
phosphorylate the intracellular tail of the long isoform receptor at Tyrosine (Y) 985, Y1077 and
Y1138. The phosphorylation of these tyrosines facilitates the recruitment of a variety of STATS,
in particular the phosphorylation of Y1138 attracts STAT3. Once the STATS are activated they
homodimerize and translocates to the nucleus where they induces transcription. The activation of

4

STAT3 leads to an increase in Suppressor of Cytokine Signaling 3 (SOCS3) expression. SOCS3
blocks leptin signaling by binding to Y985 and preventing STAT activation. Since SOCS3 is
increased as STAT3 becomes activated, STAT3 controls its own negative feedback mechanism.
(Frühbeck 2006, Lago 2008, Robertson 2008). Diagram 1.2 summarizes the leptin intracellular
signaling process.
Leptin production is controlled by many means but one of the most significant is the
presence or absence of insulin. During fasting or starvation, insulin levels decrease causing a
decrease in leptin levels. Although leptin does affect a variety of cells throughout the body it
exerts its main affects on the brain because it contains the largest population of LepRb
expressing neurons, found in the hypothalamic nuclei. Within this population there are two subtypes of neurons, one that makes orexigens neuropeptides agouti-related peptide and
neuropeptide and the other which other makes anorexigenic pro-hormones pro-opiomelanocortin
[Elmquist 1999, Schwartz 2000]. The decrease in leptin promotes hunger; once an individual
eats, insulin levels increases. The marked increase in insulin concentration in the blood results in
leptin production. The presence of leptin causes depolarization of the neurons and results in an
increase in pro-hormone pro-opiomelanocortin. The increase in hormone production causes a
signal of satiety; appetite is therefore controlled by concentrations of leptin in the blood stream
and hormone production (Ganong 2005, Elmquist 1999, Schwartz 2000, Cowley 2001).
It was originally thought that leptin only controlled appetite and energy expenditure
(Peltz 2007) but recent studies have shown that it affects many systems; of particular interest is
the endocrine system. Leptin alters hormone production and in turn affects multiple systems such
as the reproductive (Aydin 2008, Hill 2008, Schubring 1999, Cioffi 1998, Holness 1999),
digestive (Friedman 1998, Frühbeck 2001, Mizuta 2008), nervous (Nogueiras 2008, Gao 2008),
5

circulatory (Sabatier 2008, Fouillioux 2008, Sierra-Honigmann 1998, Correia 2004) and immune
systems (La Cava 2004, La Cava 2003, Hukshorn 2004, Seufert 2004, Fantuzzi 2006, Lam 2006,
Mattioli 2005, De Rosa 2007, Dellas 2007, Mattioli 2007, Lago 2008). Diagram 1.3 from La
Cava 2003 review, demonstrates leptin’s effect on the endocrine system as well as altered
function of various systems. Leptin’s effect can be seen throughout the body; its receptors have
been identified in many cell types including immune cells (Tartaglia 1994). Table 1.1
summarizes leptin’s wide reaching effect on a number of body systems.
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Diagram 1.1 Leptin Receptor Isoforms - This diagram illustrates the 6 different known
isoforms of the murine leptin receptor. All receptors have identical extracellular ligand-binding
domains but they each contain different C-terminus ends. Only the soluble receptor (Ob-Re) does
not have a transmembrane domain. The long Isoform Ob-Rb is the only receptor capable of
activating the JAK2-STAT3 pathway. With in the cytoplasmic domain are Box 1, 2 and 3. The
box 1 motif is required for JAK2 activation, Box 2 activity has not been verified but it is thought
to be required for JAK2 maximal activation. Finally the long isoform (Ob-Rb) contains three
conserved tyrosines (Y985, Y1077, and Y1138) which function as docking sites for STAT3.
(Lago, 2008)
7

Diagram 1.2 Leptin Signaling Pathway - Leptin binds to its receptor causing a conformational
change that reveals binding sites for JAK2 on box 1 and 2. JAK2 then phosphorylates itself and
the receptor particularly on Y985, Y1077 and Y1138. Phosphorylation of Y1077 and 1138
recruits STAT 5 & 3, phosphorylation of Y985 activates SHP2 and ERK MAPK pathway. Both
MAPK and STAT then regulate gene expression. The activation of STAT3 leads to an increase
in SOCS, its negative feedback mechanism, therefore STAT3 and SOCS regulate leptin
signaling. (Robertson 2008)
8

Diagram 1.3 Leptin Effects on the Endocrine System - The effect of Lepton on the endocrine
system leads to alterations in function and protein production of multiple systems. (La Cava
2003).
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Table 1.1.

Table 1.1 Leptin’s Effect Over Distinct Body Systems - This Table was created to summarize
known effects of leptin on a variety of systems. (Friedman, Frühbeck, Peltz 2007, Aydin 2008,
Hill 2008, Schubring 1999, Cioffi 1996, Holness 1999, Mizuta 2008, Nogueiras 2008 Gao 2008
Sabatier 2008, McCully, Fouillioux 2008, Sierra-Honigmann 1998, Correia 2004, La Cava 2004
La Cava 2003, Hukshorn, 2004, Seufert, 2004, Fantuzzi 2006, Lam 2006, Mattioli 2005, De
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Rosa 2007, Dellas 2007, Mattioli 2008, Lago 2008)
The Immune System
The function of the immune system is to protect the host from microbial invasion and
from tumorigenesis. To accomplish this, the immune system utilizes a bipartite approach: a fast
responding and non-specific response (innate immunity) and a slow and extremely specific
response (adaptive immunity). The innate branch is the first responder to an insult on the
organism; it includes phagocytic cells such as macrophages (MФ), neutrophils, and dendritic
cells (DC) plus product-secreting cells such as mast cells, basophils, eosinophils, and
granulocytes (Cruse 1999). These cells do not have the capacity to specifically recognize a
pathogen but do however, recognize specific components of the pathogen through the use of
Toll-like receptors (TLR) (Watts 2007). The main function of these cells is to contain the
microbe or tumor until adaptive immunity is developed or recalled, responding immediately to
the insult (Janeway 2005). Adaptive immunity is composed of lymphocytes known as T and B
cells. This branch of the immune system has the capacity to recognize a specific pathogen and
mount a response uniquely targeted to the invader. Unlike innate immunity, adaptive immune
cells respond slowly taking days or weeks to mount an effective attack. To activate adaptive
immunity, innate immune cells must inform adaptive immune cells of the invasion. This is done
via a series of chemical protein signals called cytokines and through direct interactions between
innate and adaptive immune cells.
DCs are exclusively unique to the immune system. At first glance they seem to merely
mimic macrophage activity by sampling their environment and presenting peptide to T cells; but
they alone hold the key to link the innate and adaptive branches of the immune system. DCs,
phagocytose material, process it and migrate from tissue to draining lymph nodes to present
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peptide fragments of ingested material to T cells. They are the only cells capable of directly
activating naïve T cells and are therefore required to develop immunity and clear infections or
tumors. Functionality of DC and expression of cell surface molecules varies depending on
maturity status (Alberts 2002, Kindt 2007, Cruse 1999). Immature DCs are primarily phagocytic,
expressing relatively low levels of cell surface activation markers needed for interactions with T
cells. Mature DCs possess antigen processing and presentation capabilities and express high
levels of cell surface activation markers. A significant difference between immature and mature
DC is a change in morphology, caused by re-organization of the cytoskeleton. The
morphological change greatly affects DC-T cell interaction. It is during these interactions, that T
cells ultimately decide whether to become activated or not. Exactly how this decision is made is
still not fully understood, although it is known that cytokines, DC maturation status, and DC-T
cell interactions play a major role (Kindt 2007).
DCs induce activation of both CD4+ T cells, which are characterized as helper T cells
since they secrete cytokines that coordinate the activities of all responding immune cells, and
CD8+ T cells, which are cytotoxic T cells. For the helper T cells, there are two potential types of
responses, T helper 1 (TH1) or T helper 2 (TH2). The type of response is dependent on the
pathogen as well as T cell exposure to cytokines before and during peptide presentation and is
uniquely designed for clearance of the specific invader. Bacterial and viral infections typically
promote a pro-inflammatory response known as TH1, which is marked by the production of
interleukin (IL)-12 (IL-12) and interferon gamma (IFNγ). Parasitic infections and allergens tend
to promote production of IL-4, IL-5, IL-9, IL-10, and IL-13, which is generally described as an
anti-inflammatory response. The different types of cytokines are secreted by both adaptive and
innate cells but secretion of cytokines from innate cells appear to determine the response type
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generated by adaptive immune cells (Kindt 2007).
The purpose of the immune system is to protect the host organism against disease or
infection but it can however, occasionally become auto-reactive, meaning self tissues are
targeted for destruction. This is known as autoimmunity and occurs because the system is
recognizing self antigen and is becoming activated in response to these self components.
Autoimmune diseases include type 1 diabetes mellitus (destruction of the beta islet cells of the
pancrease) (Havari 2004), Systemic Lupus Erythematosus (SLE) (Lopez 2003), Multiple
Sclerosis (destruction of the myelin sheaths of the central nervous system) (Williams 1994) or
Rheumatoid Arthritis (destruction of joint collagen) (Rannou 2005).
The actual cause of autoimmune disease is unknown and is particularly difficult to study
since the clinical manifestation of the disease occurs when approximately 80% of the tissue has
been affected (Havari 2004). However, pathogenic autoimmunity has been strongly linked to
genetic characteristics as well as environmental factors (Janeway 2005). To limit the possibility
of destructive autoimmunity, the immune system has developed a series of checkpoint processes
to induce a status known as immune tolerance, which is characterized by the lack of pathogenic
immunity (Janeway 2005). If any of the checkpoints fail and autoimmunity occurs, treatments
are available but vary depending on the target tissue (whether it is systemic or organ-specific);
however, treatments typically include global immunosuppressants with supplementation of the
lost protein if possible (insulin for example) (Bruce 2002, Janeway 2005, National Center for
Chronic Disease Prevention and Health Promotion 2005).

Obesity and Inflammation
Obesity plays a role in an assortment of diseases affecting any/or all organ systems of the
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body. High concentrations of leptin in the serum seem to increase susceptibility to autoimmune
and infectious diseases. This may be because leptin seems to act as a pro-inflammatory cytokine
(Faggioni 2001). Not only is it produced by inflammatory regulatory cells but it is also produced
and secreted into the serum in increased amounts in the presence of other inflammatory
cytokines (Sanna 2003, Faggioni 2001). Due to leptin’s inflammatory nature it is thought that
high amounts of circulating leptin promotes a rich environment for autoimmune disease.
Bokarewa found an apparent increase in leptin levels in most patients with rheumatoid arthritis
(RA). In this disease highly associated with inflammation, it was shown that patients with lower
leptin serum levels exhibited a decrease in disease symptoms. More importantly they produced a
lower amount of TH1 cytokines with an increase in TH2 cytokines that lead to a decrease in
CD4+ T cell activity (Fraser 1999). In both an Antigen Induced Arthritis (AIA) and ZIA mouse
model of immune-mediated joint inflammation, a decrease in inflammation, antibodies and proinflammatory cytokines in mice with dysfunctional leptin receptors (Lepdb) or leptin deficiency
(Lepob) was observed in comparison with B6 mice. In addition an increase in anti-inflammatory
cytokines was detected (Fraser 1999, Bernotiene 2004).

Similar results were found using

experimentally induced colitis, experimental autoimmune encephalomyelitis, type I diabetes and
experimentally induced hepatitis (Otero 2005). These studies all strongly infer that leptin and its
signaling is crucial for inflammation and immune responses.

Leptin Immunity and Dendritic Cells
Several studies have demonstrated that various cells of the immune system, both innate
and adaptive, express the signaling isoform of the leptin receptor (Tartaglia 1995). Moreover,
the same studies have demonstrated a direct affect of leptin on these cells. MФ in the presence
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of leptin have been found to increase phagocytosis and processing capability due to a dramatic
increase in production of oxidative species (H. Zarkesh-Esfahani 2004, P. Mancuso 2004, G.M.
Raso 2002, F. Caldefie-Chezet 2001, F. Caldefie-Chezet 2003). This therefore enhances function
and ability to remove debris, dead and dying cells and pathogens. In 2007 Dellas noted
thrombocytes expressing leptin receptors appear to enhance agonist-induced platelet aggregation
(Dellas 2007). This effect is both beneficial and counterproductive since clotting prevents
excessive bleeding but can also cause cardiovascular problems including blood clots and
aneurisms. The presence of leptin promotes production and maintenance of B cells (Kate
Claycombe 2006) as well as promote proliferation, differentiation, activation and cytotoxicity of
natural killer (NK) cells (Z. Tian, R. Sun 2002) and. For T cells, leptin has been proven to
promote T cell activation, inhibit production of Treg cells (De Rosa 2007) and push for TH1
responses by promoting production of pro-inflammatory cytokines (Lam 2006).

However,

leptin’s effect on all immune cells is still not fully understood. Its affect on DCs remain largely
elusive, recent findings suggest it may play a role in DC activation (Lam 2006, Mattioli 2005).
In this study, we focus on the effect of leptin on DC because of their critical role in
linking the two branches of the immune system together. In 2005, Mattioli et al demonstrated
that human DC express all six isoforms of the leptin receptor, including the long receptor OB-Rb
which has the ability to signal intracellularly when bound by its ligand. Recent work on human
DC by Mattioli (Mattioli 2008) demonstrated that leptin induces morphological changes such as
actin microfilament rearrangement leading to uropod and ruffle formation. Mattioli also
demonstrated that leptin enhances human DC activation in the presence of lipopolysaccharide
(LPS). We believe that the morphological and functional changes induced in DC by leptin
promotes the pro-inflammatory state observed in obesity due to the enhanced interaction with T
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cells (as a direct result of increased surface area) and promotion of a TH1 response. We therefore
proposed to verify these findings in a murine system to ultimately assess whether these findings
have any physiological significance in vivo. We hypothesized that leptin increases the number
and length of dendrites in DCs by causing a re-arrangement of the cytoskeleton, which leads to
an increased capacity to migrate and to activate T cells. In this study, we aimed to determine the
effects of leptin on DC cytoskeleton re-arrangements, on DC migration ability, and on DC ability
to activate T cells. This study will help to elucidate leptin’s affect on DC morphology and
functionality specifically in regards to a high concentration of exogenous leptin, which will
mimic the condition of obesity and could help to elucidate its potential role obesity-associated
inflammation.
Overall the presence or absence of leptin can enhance immune responses; Since leptin
has been shown to promote a pro-inflammatory environment, enhance MФ and T cell activity as
well as suppress T reg production it is evedent that obesity increases the probability of an
individual to develop autoimmune disorders. In this study we proposed that leptin also
potentiates DC function, therefore increasing the likelihood for an autoimmune disease to
develop. It is critical to understand the effect leptin has on DCs since they are the link between
the innate and adaptive branches. Although MФ are able to prime memory and activated T cells,
their main purpose is to maintain T cells activated and direct them to the site of infection. DC
however, are the only cell type known to be capable of activating naïve T cells to produce a
robust immune response. Therefore, activation of the adaptive immune system is primarily
orchestrated through DC-T cell interactions (Cruse 1999). Diagram 1.4 summarizes known
effects of leptin on immune cells.
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Diagram 1.4 Immunological Role of Leptin - Summary of the mass effect of leptin in
modulating the immune system. (Caldefie-Chezet 2001, Caldefie-Chezet 2003, Claycombe 2006,
De Rosa 2007, Dellas 2007, Mattioli, 2007, Mancuso 2004, Raso 2002, Tian 2002, Lam 2006,
Straface 2005, Zarkesh-Esfahani 2004)
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CHAPTER 2

ASSESSMENT OF THE EFFECT OF LEPTIN ON CYTOSKELETAL
RE-ARRANGEMENT OF DENDRITIC CELLS

Dendritic cells received their name because of the protrusions that extend from their
bodies, which resemble neuronal dendrites. Immature DCs have a limited number of dendrites
and are much more circular in shape while activated/mature DCs have numerous dendrites that
vary in length and width. The protrusions are formed by the cytoskeleton (Dancker 1975, and
Vandekerckhove 1985).
The cytoskeleton is vital for growth and division of all cells. It provides shape,
resistance/rigidity, and allows for locomotion and proper internal structure. It is composed of
three basic filaments, each with a different function. Intermediate filaments are ropelike and give
the cell strength. Microtubules direct intracellular transport and aid in cellular division.
Structurally they are long hollow cylinders made of protein tubulin. Actin filaments are highly
flexible, they are commonly known as microfilaments. Usually these microfilaments are
distributed throughout the cell but are concentrated just below the plasma membrane an area
called the cortex. Actins’ main function is to provide a shape for the cell surface, and to promote
migration. Accessory proteins, including motor proteins, are necessary to assemble the different
components of the cytoskeleton. They regulate distribution and dynamic behavior of the three
filaments by binding to them and “directing traffic”, taking into consideration extracellular and
intracellular signals. Mature DCs contain increased projections and length of projects known as
lamellipodia, which also increases DC cell surface area, potentially augmenting DC ability to
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migrate and increasing their ability to interact with multiple T cells at the same time (Alberts
2002).
There are two basic forms of actin, G- and F-actin. Its size ranges from 42 - 45 kDa
(Pollard, T.D. 1998, & Kuhn J. R, 2005). G-actin is the free globular monomer form of actin
found throughout the cytoplasm. This monomer can dimerize and trimerize to form polymers,
known as filamentous actin (F-actin). The purpose of creating F-actin is to aid in many cellular
processes such as compartmental movements, internal support, cell shape and size. The initiation
to convert the monomer to dimers or trimers is slow but once begun elongation occurs rapidly
(Pollard, T.D. 1998, & Kuhn J. R, 2005). This process requires energy in the form of Adenosine
Triphosphate (ATP). G-actin therefore binds to ATP and hydrolyzes the nucleoide to produce a
weak non-covalent bond to another actin molecule. Additionally it is then bound to Adenosine
Diphosphate (ADP) (Susan Nicholson-Dykstra, 2005).

At this point the addition of more

monomers occurs in a polar direction where the faster growing end is known as the plus end and
the slower growing end is the minus end (Pollard, T.D. 1998, & Kuhn J. R, 2005).
Total cellular actin exists in flux between the monomer and polymer form. Actin
filaments are composed of the globular actin subunits; these subunits polymerize to produce a
two-stranded helix. They are associated in linear bundles that can produce a two dimensional
network or a three-dimensional gel. Since filamentous actin subunits are held together by noncovalent interactions they are extremely unstable. This facilitates movement and rearrangement
of the actin filaments, thus, easily manipulating cellular morphology as necessary.
Distinct morphological differences are observed between immature and mature DC. As
stated previously, resting/immature DCs possess limited numbers of dendrites and are more
rounded in shape; activated/mature DCs possess numerous dendrites that vary in length and
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width. Immature and mature DCs also differ functionally. Immature DCs excel at acquiring
antigen but have limited presentation capabilities. Mature DCs have limited antigen acquisition
but are far superior at presenting and activating T cells. Changes in DC morphology are directly
linked to changes in DC function.

Differentiation from a resting/immature state to an

activated/mature state is accompanied by an increase in dendrite numbers and length. The
morphological change is thought to enhance the ability of DC to migrate towards T cells in the
secondary lymphoid organs and to enhance DC – T cell interactions. Our preliminary data
demonstrated that the addition of exogenous leptin to bone marrow (BM)-derived DC promoted
the formation of dendrites (increase in number or an increase in length). For DC derived from
human peripheral blood mononuclear cells (PBMCs), leptin was shown to enhance uropod
formation (Mattioli 2008). We therefore hypothesized that one potential effect of leptin receptor
ligation on DC is to increase the DC surface area by promoting dendrite formation and thus
enhancing DC migration and interactions with T cells.

We further hypothesized that the

changes in DC morphology visualized upon treatment with exogenous leptin resulted directly
from changes in actin architecture.

Results
To visualize actin re-arrangement and morphological change of DC upon treatment with
leptin, we used two types of microscopy: a) light microscopy, and b) confocal microscopy. Light
microscopy was used to assess gross morphological changes and confocal microscopy was
utilized to assess the localization of actin filaments. DCs were differentiated from bone marrow
(BM) stem cells of C57BL/6 mice in the presence of granulocyte monocyte/macrophage colony
stimulating factor (GM-CSF) and interleukin-4 (IL-4). On day 6, the DCs were enriched by
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positive selection for CD11c-positive cells and were allowed to rest for 24 hours; the purified
BM-DC were then treated with one of the following conditions:

Treatments were as follows:
1.) 1 µg/mL of Ob-R-Fc
2.) Non-treated DC in RPMI 1640 media
3.) 10 µg/mL LPS
4.) 160 ng/mL recombinant murine leptin
5.) 10 µg/mL LPS + 160 ng/mL recombinant murine leptin
6.) 16 ng/mL recombinant murine leptin
7.) 10 µg/mL LPS + 16 ng/mL recombinant murine leptin.

Non-treated cells functioned as negative controls. To demonstrate that potential changes
observed were directly due to addition of exogenous leptin, the Ob-R-Fc chimera was used. The
chimera is a fusion between the extracellular domain of the leptin receptor and the Fc portion of
an immunoglobulin (Ig). The chimeric protein is soluble and binds to leptin, preventing it from
ligating cell surface-bound leptin receptors. Thus, Ob-R-Fc treatment blocks bovine leptin found
in the media from the serum supplement (which can bind to murine leptin receptors) and served
as an additional negative control. Lipopolysaccharide (LPS) functioned as a positive control for
DC maturation. A low (10 ng/ml) and high (160 ng/ml) concentration of leptin was chosen
based on circulating levels of leptin found in studies of Mexican Americans by Peltz (Peltz
2007).
Following a 24 hr treatment period, light microscopy images were obtained from the
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treated BM-DC with a magnification of 40X and are pictured in Figure 2.1. As was expected,
there is no noticeable change in cell morphology between the Ob-R-Fc-treated and media treated
cells (Figure 2.1A and 2.1B), suggesting that the leptin concentration in the bovine serum
concentration in the media is not significant enough to cause any detectable morphological
changes.

In contrast, the positive control, LPS-treated cells presented with distinct

morphological changes in the form of increased dendrite length, number, and thickness (Figure
2.1C). Interestingly, a similar change was induced with leptin treatment alone [Figure 2.1D (160
ng/ml) and 2.1F (16 ng/ml)]. Of particular note is the combination of leptin and LPS treatment,
which produced the most significant observable changes [Figure 2.1E (160 ng/ml leptin +
10µg/ml LPS) and 2.1G (16 ng/ml leptin + 10µg/ml LPS)]. The leptin plus LPS treatment
increased the total number of DC with observable dendrites and induced a marked increase in the
number of dendrites per DC. Moreover, the higher concentration of leptin (160 ng/ml), induced
the most pronounced morphological change.
For confocal microscopy, BM-DC were generated, purified, and treated as previously
described. Following the 24 hour treatment, the cells were fixed, permeabilized, and then stained
with rhodamine-labeled phalloidin to visualize filamentous actin (F-actin) and were
counterstained with the nuclear stain 4',6-diamidino-2-phenylindole (DAPI) to facilitate cell
orientation. Due to the required centrifugation of the purified BM-DC onto the microscope
slides, dendrite morphology is lost, although not entirely. Thus, the formation of ruffles or
lamellopodia is used as a signature of morphological changes. As shown in Figure 2.2, the
control samples [Ob-R:Fc-treated (Figure 2.2A) and non-treated (Figure 2.2B)] presented with
little to no membrane ruffles, with the Ob-R:Fc-treated BM-DCs appearing slightly rounder than
that of the media treated DC. In addition, the intensity of rhodamine staining for these two
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treatments is quite dim, demonstrating weak levels of F-actin. For the positive control (LPStreated DC figure 2.2C), spikes of dendrites are visible and F-actin levels are increased above
that of both negative controls [Ob-R:Fc-treated (Figure 2.2A) and media treated cells (Figure
2.2B)]. Leptin treatment alone markedly enhanced the formation of lamellopodia [Figure 2.2D
(160 ng/ml leptin + 10µg/ml LPS) and 2.2F (16 ng/ml leptin + 10µg/ml LPS)] and caused an
intense localization of F-actin at the peripheral edges of the cell. Moreover, the extent of
morphology change and F-actin intensity is proportional to leptin concentration. Leptin plus
LPS appears to greatly elongate and define the llamellipodia and dendrite spikes much more so
than the LPS alone [Figure 2.2E (160 ng/ml leptin + 10µg/ml LPS) and 2.2G (16 ng/ml leptin +
10µg/ml LPS)] and is also proportional to leptin concentration. However, the intensity of F-actin
is decreased with the combination treatment.
To better assess the relative amounts of filamentous actin present in the differentially
treated DC, microscope software was used to quantitate the intensity of fluorescence of
rhodamine-phalloidin (Figure 2.3). The data was collected as surface area, mean intensity (MI)
and MI/µm2. Analysis of 30 cells at each treatment was performed. Table 3 contains a summary
of the results obtained. Quantification of confocal studies further supports leptin’s ability to
rearrange the cytoskeleton of DC as evidenced by an increase of overall surface area increase in
dendrite number and length as well as an increase in F-actin intensity when comparing the leptintreated DC to the non-treated control. The addition of LPS to the leptin treatment did not
augment the morphological changes promoted by leptin; in fact, the combination treatment was
less effective than either treatment alone. Of interest are the changes induced by the low versus
high concentrations of leptin. The low concentration (16 ng/ml) of leptin almost triples the
relative amount of F-actin and increases the total surface area by a little more than double. The
23

high concentration of leptin (160 ng/ml) induces a five-fold increase in F-actin but does not alter
surface area. Despite the different results, both concentrations of leptin induced significant
morphological changes in DC.
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Figure 2.1 Leptin Enhances Dendrite Formation in BM-DC: Light microscopy of DC
enriched on day 6 and treated for 24 hours as indicated.

Magnification at 40X Data is

representative of three separate experiments. (A.) chimera, (B.) media, (C.) LPS, (D.) leptin
160ng/ml (E.) L+L 160 ng/ml, (F.) Leptin 16 ng/ml, (G.) L+L 16ng/ml
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Figure 2.2. Leptin Enhances F-Actin Polymerization. Day six BM-DC were enriched and then
treated for 24 hours with the indicated reagents. The cells were then harvested, fixed onto
microscope slides, stained with rhodamin-phaloidin (red), counterstained with DAPI, and were
then analyzed by confocal microscopy. Panel A: Ob-R:Fc; Panel B: non-treated; Panel C: LPStreated; Panel D: 160 ng/ml leptin; Panel E: . 160 ng/ml leptin + LPS; Panel F: 16 ng/ml leptin;
and Panel G: 16 ng/ml leptin + LPS. All images were acquired at the same gain, pinhole size
156 µm and magnification of 63X (oil emersion).
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Figure 2.3. Surface Area and Mean Intensity Analysis of Leptin-Treated DC: Day six BMDC were enriched and then treated for 24 hours with the indicated reagents. The cells were then
harvested, fixed onto microscope slides, stained with rhodamin-phaloidin (red) and then
analyzed by confocal microscopy. Panel A: Ob-R:Fc; Panel B: non-treated; Panel C: LPStreated; Panel D: 160 ng/ml leptin; Panel E: . 160 ng/ml leptin + 10 µg/ml LPS; Panel F: 16
ng/ml leptin; and Panel G: 16 ng/ml leptin + 10 µg/ml LPS. Data is representative of 30 cells per
treatment.
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Table 2.1.

Table 2.1. Leptin Induces Marked Changes in DC Morphology - The following parameters
were assessed using Zeiss Scanning Confocal Microscope with Pascal Deconvulution TimeLapse Temp Control software.: Mean Intensity (MI) Surface Area (SA) and MI/µm2, Number of
Dendrites and Length of Dendrites. Data presented on this table is the mean of 30 cells per
treatment.
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The microscopy data demonstrated that treatment of DC with a low and high, yet
physiological, concentration of leptin induces morphological changes similar to those observed
in the human system. Maximal effects were observed at 160 ng/ml of leptin and minimal
changes were observed at 16 ng/ml of leptin; therefore further studies were conducted at 160
ng/ml of leptin to determine actin content and form.
To quantify changes induced by leptin to actin, whole cell lysates as well as cytoskeletal
and soluble protein fractions were prepaire. quantified by Western blot (WB) analysis with
densitometry and actin indirect-ELISA. The purpose of fractional cell lysates was to separate the
polymer form of actin (F-actin), found in the cytoskeleton, from the monomeric form (G-actin)
found in the cytoplasm. Western blots and densitometry analysis of total cell lysates illustrated
that in comparison to the negative controls, leptin causes little to no increase in overall actin
(Figure 2.4).

In comparison to media treatment, G actin WB and densitometry showed a

decrease in actin in chimera treatment and an increase in LPS, Leptin and L+L (in increasing
order) (Figure 2.5). Furthermore, F actin WB and densitometry showed a slight increase in
Leptin, LPS, and L+L treated DC (from smallest increase to largest increase) (Figure 2.6B)
Ratios of treated DC in G vs F actin were as follows: Media = 7:5, Chimera = 26:25, LPS =
11:10, Leptin = 161:125, L+L = 103:100. This demonstrated that leptin induces an increase in
both G and F-actin.
Indirect actin Enzyme Linked Immunosorbent Assays (ELISA) was performed because it
is a far more sensitive technique that may detect minute differences; additionally it is much more
quantifiable (Figure 2.4). To some extent results from ELISA mirrored those from WB analysis
(Figure 2.2 and Table 2.1). Using whole cell lysates, a slight increase in total actin expression
was detected in leptin and LPS treated cells however this was not significant (Figure 2.7A). This
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strongly somewhat implies that the addition of leptin in combination with LPS causes an increase
in actin production in comparison to media, OB-R:Fc or LPS, but the reason for this is unclear.
Indirect ELISA also demonstrated differences in DC content of F and G actin caused by the
distinct treatments. An increase in G-actin in LPS and L+L treated DCs was observed however,
leptin, media and OB-R:Fc remained unchanged and equivalent to one another (Figure 2.7B).
Furthermore, ELISA test revealed that leptin, LPS and leptin + LPS express an increase in Factin with L+L showing the largest increase followed by LPS then leptin, once again non-treated
and OB-R:Fc treated cells remained unaltered and equivalent (Figure 2.7C).

Conclusion
Analysis of confocal data demonstrated an increase in surface area, number of dendrites
and length of dendrites in leptin, LPS and leptin + LPS treatments; therefore their F-actin MI
(rhodamine) was lower than that of non-treated media cells. However this does not signify a
decrease in F-actin in comparison to OB-R-Fc, rather a dispersal of F-actin throughout the cell to
cover a larger area.
Leptin, LPS and L+L cause little to no increase in actin production. G-actin and F-actin
levels also increase in all 3 treatments. Leptin treatment increases amount of F actin but LPS is
more efficient at this, the duo leptin and LPS treatment is even more successful this is possibly
due to the increase in available G-actin within the treated cells. We believe that there is a rapid
shift from G to F-actin and F to G-actin that may be due to effects on actin-modulating proteins
that allow for rapid assembly and disassembly of actin. Therefore F actin may be increasing in
treated DC because there is more G actin available at a given time. The ratios of G vs F-actin
may therefore not be changing a great deal between treatments but the amount of F actin is
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increasing, this change may ultimately lead to altered cell morphology.
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Figure 2.4. Leptin Causes an Increase in Overall Actin. Whole cell lysates were obtained
from DC treated for 24 hours with the indicated reagents. 5 µg/lane of protein were loaded from
each treatment onto lanes of an 8% SDS Gel (A). Densitometry was conducted on the bands
obtained (B). Data is one of three representative experiments.
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Figure 2.5. Leptin Treatment Increases the Amount of Soluble Actin (G-Actin) Monomeric
fractioned lysates were obtained from DC treated for 24 hours with the indicated reagents. 5
µg/ml were loaded from each treatment onto lanes of an 8% SDS Gel (A). Densitometry was
conducted on the bands obtained (B). Data is one of three representative experiments.
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Figure 2.6: Leptin-Treatment Increases the Amount of F-Actin. Polymeric actin (Fractioned
lysates) was obtained from DC treated for 24 hours with the indicated reagents. 5 µg/ml were
loaded from each treatment onto lanes of an 8% SDS Gel (A). Densitometry was obtained on the
bands obtained (B). Data is one of three representative experiments.
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A

C

B

Figure 2.7. Measurement of Total, G-, and F-Actin by Indirect ELISA - Whole cell lysates
(A) or fractioned lysates (B. Monomeric actin and C. Polymeric actin) were obtained from the
different populations of treated DC and were plated onto ELISA plates overnight at 500 ng/ml of
total protein. The plates were later blocked with 5% non-fat dry milk, then incubated with a
primary anti-actin antibody followed by a second incubation with horse radish peroxidaseconjugated secondary antibody. Chromogen was then added and the plate was read on a
spectrophotometer at 450nm. Data is presented as the mean ± SEM of duplicate wells and is
one of two representative experiments.
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CHAPTER 3

ASSESSMENT OF THE EFFECT OF LEPTIN ON DENDRITIC
CELL FUNCTION IN TERMS OF MIGRATION

Dendritic cells are naturally mobile cells that sample their environment and report their
finding to T cells in the form of peptide antigen. They are located in all tissues throughout the
body and form part of the innate immune system. Their role within the system as a whole is
crucial because they alone hold the key to link the innate and adaptive immune systems. DC
phagocytes material, process it and migrate from tissue to draining lymph nodes to present
peptide to T cells. They are the only cells capable of directly activating naïve T cells and are
therefore required to clear infections and develop immunity. While in situ, they phagocytosis
and pinocytosis their surroundings. The ingested material is placed in phagosomes or endosomes
which fuse withy lysosomes to create phagolysosomes. The pH within these phagolysosomes is
very low and enzymes within the compartment break the antigen down into peptides of 8-30
amino acids in length. The newly formed peptides are placed on MHC II to be presented to T
cells. If the ingested material is an infected cell or a pathogen, the DC receives a signal to
become activated. The signal is received through the Toll-like receptors binding to unique
pathogen-derived ligands (Abbas 2006).
These APCs contain unique characteristics; because they are phagocytic cells they
express a MHC class II molecule to present processed material to T cells. Other cell surface
molecules commonly found on DCs, include CD11c (most frequently used to purify cells) as
well as CCR7 (chemokine receptor for CCL19 ), CCR5 (chemokine receptor for CCL4 ), CD40
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(DC activation marker), CD54 (Adhesion molecule to stabilize DC-T cell interaction), CD80
(DC and T co-stimulatory molecule), and CD86 (DC and T co-stimulatory molecule).
Functionality of DC and expression of these cell surface molecules varies depending on maturity
status (Alberts 2002, Kindt 2007, Cruse 1999). Immature DCs phagocytose very well and have
lower concentrations of MHC II CD40, CD54, CD80, and CD86 than mature DC. The presence
of a high concentration of the chemokine receptor, chemokine C-C motif receptor 5 (CCR5) is
indicative of immature DC. Upon activation by a pathogen or exposure to foreign material their
phagocytic ability and CCR5 receptor diminishes as chemokine C-C motif receptor 7 (CCR7)
appears. This receptor allows for the migration of DC to the draining lymph nodes and is
indicative of a mature or maturing DC (Alberts 2002). During the maturation process MHC class
II, CD40, 54, 80, and 86 are all up-regulated to enhance the DCs ability to present peptide to T
cells (Alberts 2002, Kindt 2007, Cruse 1999). One significant difference between immature and
mature DC is the obvious change in morphology, caused by re-organization of the cytoskeleton.
The morphological change greatly affects DC-T cell interaction (Kindt 2007). Diagram 3.1
summarizes the stated differences between mature and immature DC.
One of the most important differences between mature and immature DC is the change in
chemokine receptors on the cell surface. This up-regulation of CCR7 and down-regulation of
CCR5 facilitates the migration of the DC to the draining lymph node (where T cells are located).
As described DC mobility is required for adequate presentation capabilities of these APCs;
therefore migration is a crucial process for capacity to present antigen and likelihood to activate
both naïve and primed T cells (Butcher 1996, Ansel, 2001and Von Andrian 2000).
The process of migration is complex and requires a number of different cellular
components, signals, and attractants that vary depending on cells status (immature or mature);
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this is true for most leukocytes. The process of migration is usually initiated by the presence of a
chemoattractant such as a chemokine. Cells migrate towards theses 8-10 kDa proteins by
following the concentration gradient towards the higher concentrations. As described, DC
express a variety of cell surface markers that vary by maturity status. As immature, DC they
express high levels of a CCR5 whose ligand is Macrophage Inflammatory Protein-1α (MIP-1α)
or Macrophage Inflammatory Protein-1β (MIP-1β). However, as mature DC they decrease
expression of CCR5 to increase expression of CCR7. This receptor responds to ligand
chemokine C-C motif ligand 19 (CCL19) which recruits the mature DC toward the secondary
lymphoid organs (Muller 2003). Migration towards the lymphoid organs increases the
probability of DC to encounter T cells specific for the peptide they care and therefore provoke an
immune response.
One key component to successful DC migration is morphological changes that ultimately
result in cytoskeletal plasticity. This allows DC to navigate through interstitial tissues, blood and
lymph (Worthylake 2001). The cytoskeleton is composed of microfilaments, intermediate
filaments, and microtubules. Migration is characterized by polymerization of actin, one of the
key components of the cytoskeleton (microfilaments) who is primarily responsible for cellular
morphology and movement. Thus, migration is typically due to altered cellular morphology
caused by changes in the ratios between the monomer globular and the polymer filamentous
forms of actin and the rearrangement of the actin filaments. Actin dynamics is therefore the
primary cause of membrane protrusions and cell matrix adhesion that result in cell migration.
Enhanced migration could possibly increase the chance of DCs activating T cells specific
for the peptide they are carrying by limiting the time spent migrating and maximizing the time
DCs spend interacting with T cells. This could be crucial, because the amount of time a DC and
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T cell interact may affect the efficiency and efficacy of the resulting response. We therefore
hypothesize that leptin promotes DC migration towards draining lymph nodes due to increased
lamellipodia formation.

Results
DC migration was assessed by placing enriched murine bone marrow derived DC into 24
well 10 µm transwells. DC grown in culture in the presence of GM-CSF and IL-4 as indicated in
materials and methods. For all experiments conducted purity of enrichment was greater than 90
percent as demonstrated by flow cytometry (data not shown). DC were treated as described in
chapter 2 for either 24 or 48 hours [Treatments were as follows: 1.) Non-treated DC in RPMI
1640 media 2.) 1 µg/mL of Ob-R-Fc 3.) 10 µg/mL LPS 4.) 160 ng/mL recombinant murine
leptin 5.) 10 µg/mL LPS & 160 ng/mL recombinant murine leptin. Cells were washed to remove
traces of treatment and placed in RPMI 1640 in the upper chamber of a transwell at 400,000
cells/well. DC-specific chemokine (CCL19) was placed at 200 ng/ml, 50 ng/ml and no CCL19 in
the lower chamber. The plates were then incubated at 37ºC for 4 and 24 hours. Cells in the lower
chamber were digitally photographed to assess morphology using a magnification of 40X. Cells
were finally harvested and counted by trypan blue exclusion to determine the percentage of
migrated DC.
Leptin appears to enhance DC migration as demonstrated in the 24 (Figure 3.1) and 48
hour treatments (Figure 3.2) at both 4 and 24 hour migration time-points. The X-axis of the each
graph illustrates the percentage of migrated cells, while the Y-axis of the graph indicates the
amount of CCL19, each sample was run in duplicates and the graphs represent the data of one of
three experiments but similar results were obtained in all experiments. Migration appears to
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occur in a CCL19 dose dependent manner where the higher the concentration of CCL19 the
higher the number of cells that migrated. Additionally, treatment of DCs treated with leptin, LPS
or the duo combination of leptin and LPS significantly migrated much more efficiently than the
non-treated or OB-R-Fc treated cells. However the duo treatment of leptin and LPS caused a
much greater increase in migration than leptin or LPS alone. Leptin and LPS only treatments
were comparable, lower than the duo combination but still greatly increased from the media and
OB-R-Fc treatment.
We were curious whether the migrated DC maintained the previous cellular morphology
determined in chapter 2, therefore prior to harvesting the 24 hour treated 4 hour migrated cells
digital light microscopy images at a magnification of 40X were obtained (Figure 3.3). This data
verified that the migrated cells are indeed DC, and that the successfully migrated DC were able
to maintain the cytoskeletal rearrangement caused by the treatments. Although images for the 24
hr migrations time-point and 48 hour treatment were obtained the data is not shown but similar
results were obtained.

Conclusion
Leptin may possibly play a vital role in DC migration both in immature and mature DC
as observed by the presence or absence of LPS. Additionally percent of migrated DC increased
in a dose dependent manner as the chemokine concentration increased. Digital images of
migrated DC demonstrated that DC retained their morphology post migration. It should be noted
that although DC migration was enhanced in the leptin treatment it was greatly increased in the
duo combination of leptin and LPS. Therefore leptin alone or together with LPS promotes DC
migration which is dependent on cytoskeletal rearrangements. We hypothesize that the rapid
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turnover between G and F-actin is what allows for the enhanced migration. A second possibility
is an up-regulation of the chemokine receptor CCR7. Moreover it seems that the concentration of
leptin present may affect the migrational outcome since the 24 hour treatments migrated more
efficiently than 48 hour treatments. This is noteworthy since the 48 hour treatments were not
given fresh treatment post 24 hours; therefore the concentration of the treatment decreased over
time. This may indicate that leptin’s effect is nearly immediate and that migration is dependent
on leptin serum/media levels where the higher concentrations exert a more potent effect.
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Diagram 3.1 Dendritic Cell Function Summary - This Diagram includes the discussed
characteristics of mature and immature DC. (Alberts 2002, Kindt 2007, Cruse 2007, Butcher
1996, Ansel, 2001and Von Andrian 2000)
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Figure 3.1. Leptin Enhances DC Migration Post 24 Hour Treatment: Murine bone marrow
derived DC were enriched and treated as indicated for 24 hours. 400,000 cells were placed in
each transwell, CCL19 was added to the lower chamber at 0, 50 and 200 ng/ml. Migrated DC
were harvested at 4 hours and 24 hours post incubation and counted by trypan blue exclusion.
The percentage of migrated DC was determined and graphed.
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Figure 3.2. Leptin Enhances DC Migration Post 48 Hour Treatment: Murine bone marrow
derived DC were enriched and treated as indicated for 48 hours. 400,000 cells were placed in
each transwell, CCL19 was added to the lower chamber at 0, 50 and 200 ng/ml. Migrated DC
were harvested at 4 hours and 24 hours post incubation and counted by trypan blue exclusion.
The percentage of migrated DC was determined and graphed.
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Figure 3.3 Migrated DC Maintained Morphology: Prior to harvesting of migrated cells digital
images were obtained to verify cellular morphology was maintained post migration. These are
images obtained from 24 hour treated 4 hour migrated cells. Although images for 48 hour
treatment and 24 hour migrations are not shown a similar trend was observed.
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CHAPTER 4

ASSESSMENT OF THE EFFECT OF LEPTIN ON DENDRITIC
CELL ABILITY TO ACTIVATE NAÏVE T CELLS

Adaptive immunity is composed of lymphocytes known as T cells and B cells. This
branch of the immune system has the capacity to recognize a specific pathogen and mount an
immune response directed specifically towards it. Adaptive response is delayed in comparison to
the response by the innate branch. A complete response by the adaptive immune branch requires
approximately 2 weeks time (Kindt 2007)
T cells responses are cell mediated. These cells mature in the thymus, where they
undergo a process known as VDJ recombination which determines T cell receptor (TCR)
specificity. This random process produces a vast amount of diversity, up to 1018 different
possibilities of TCRs (Janeway 2005). There are a variety of sub-populations within T cells each
with a distinct function, these include memory T cells, cytotoxic T cells, Helper T cells and
regulatory T cell. Memory T cells allow for a rapid response; they are long lived T cells that
remain in the LN to facilitate the activation process when the host encounters a pathogen a
second time. Cytotoxic T cells are CD8+, they target and kill infected cells to prevent further
infection. Helper T cells are CD4+; their main function is to provide support in the form of
cytokines, to both the innate and adaptive immune response. This action augments and facilitates
the effectiveness of all responding cells. Finally, the relatively new sub-population of T cells are
known as regulatory T cell (Treg), they function as an “off” switch to stop an immune response.
This is accomplished by producing TH1 cytokines during a TH2 immune response and TH2
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cytokines during a TH1 response to suppress the currently active immune response. One
commonly identifiable characteristic of Treg is the expression of both CD4 and CD25 on the cell
surface (Janeway 2005).
Naïve T cells living in the LN and thymus encounter many DC to scan the peptide carried
on their MHC class II molecules. Recognition of a peptide by T cells causes a complex
prolonged interaction that ultimately leads to T cell activation (Shaw 2008). For this to occur, a
multiple number of interactions must take place simultaneously. It is currently thought that T
cells require an interaction with APCs that is 4-16 hours long to actually become activated,
proliferate and secrete cytokines such as IFN-γ and IL-2 and migrate to affected areas (Huppa
J.B. 2003 and Lezzi, G. 1998).
A response to a signal requires three elements: a signal, a receptor and a signal
transducer.

For a signal, matured APCs, particularly mature DC, migrate toward the

concentration gradient of CCL19 (found in high concentrations in the lymphoid organs) and
encounter many T cells. They present processed antigen in the form of peptide on their MHC II
cells surface marker to T cells’ TCR receptors. Additionally the DC B7 family molecules (CD80
and CD86 in mice) bind to T cell CD28 molecules to co-stimulate activation and signaling in
both DC and T cells (signal 2) CD40L (CD40 Ligand) on T cells interacts with DC CD40
receptor to further activate DCs. A CD4 molecule on the T cells surface then binds to this
complex to stabilize the immunological synapse and therefore enhance adherence. This
prolonged interaction stimulates and pushes T cells into the G1 phase and induces transcription
(signal 3) of the IL-2 gene to produce CD25 (IL-2 receptor), and promotes IL-2 production 100
fold. Once the secreted IL-2 binds to surrounding T cell receptors they too begin to proliferate
and differentiate to the different sub-types of T cells. However it is unclear how the T cell
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actually commits to one particular sub-population, but it is thought that cytokines play a critical
role (Faggioni 2001). Activated T cells then secrete IFNγ to further enhance and facilitate
removal of a pathogen by activating MФ and increasing the expression of MHC II on APCs. The
newly formed population of CD8+ T cells then migrates toward the inflamed/affected area and
attacks their targets cells. Overall T cells mediate clearance of pathogens or destruction of self
tissue by enhancing APC function or puncturing infected or self tissue in the case of autoreactive T cells (Kindt 2007). A brief summary of DC-T cell interactions is illustrated in
Diagram 4.1.
Obesity and leptin appear to create a rich environment for autoimmune disorders to
develop as previously discussed. Consistently high levels of insulin and leptin cause cells to
become leptin resistant provoking an increase in circulating leptin which results a proinflammatory environment. We propose that leptin also potentiates DC function, therefore
increasing the likelihood for an autoimmune disease to develop. With regards to T cell activation
we hypothesized that increased lamellipodia will increase the DC ability to activate T cells
because the total surface area to interact with T cells is increased. This will therefore enable the
DC to present to a larger number of T cells at one time. To determine if our hypothesis was
correct we assessed the interactions of leptin-treated DC with antigen specific T cells in vitro.

Results
Antigen-specific T cell hybridoma, an established T cell line, and primary antigenspecific T cells were presented with peptide by leptin enriched (>90%) treated or untreated DC.
The T cell hybridoma is a CD4+ T cell line specific to ovalbumin peptide. It was generously
donated by Dr. Philippa Marrack from the National Jewish Medical and Research Center in
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Denver; CO. Primary T cells were obtained from TCR transgenic mice with a C57BL6
background also specific to ovalbumin. They were enriched by positive selection for CD4+ T
cells as indicated in the materials and methods. It was determined by flow cytometry that the
purity of the cells obtained was greater than 90 percent (data not shown). The use of these two
different systems provide complimentary information about T cell activation where activation of
the T cell hybridoma was measured as a function of IL-2 production (Figure 4.1) and TCR
transgenic T cell activation was measured as a function of IFNγ production (Figure 4.2) and
proliferation (Figure 4.3).
The five different DC populations/treatments were pulsed with ovalbumin peptide at 500
mg/ml, this is a simple exchange at the cell surface and does not require DC processing. The
antigen-pulsed DC were then co-cultured with the T cell hybridoma or the TCR transgenic T
cells at a ratio of 1:1, 1:5, 1:10, and 1:20 for a 72 hr incubation period. An additional group
without ovalbumin peptide at a ratio of 1:5 was added to account for background. As a positive
control DC + T cells at a ratio of 1:5 were co-cultured in the presence of 10 µg/ml of
Concanavalin A (Con A) because this is a chemical well known to activate T cells in the
presence of DC by forcing TCR MHC interactions. At the completion of the 72 hr. incubation
supernatants were removed for further analysis by ELISA for cytokine production, IL-2 (Figure
4.1) in the case of the hybridomas, and IFNγ production (Figure 4.2) in the case of the TCR
transgenic T cells. TCR transgenic co-cultures were further analyzed for proliferative
capabilities. A radio-actively labeled nucleotide ([H3]-thymidine) was added post 72 hours initial
co-culture for an additional 19 hrs. Proliferation was assessed by the incorporation of the
tritiated nucleotide and thus radioactivity was measured, where the amount of radioactivity
directly correlates with DNA replication/cellular division and therefore proliferation (Figure 4.3).
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IL-2 production (Figure 4.1) in the supernatant of the hybidoma-DC co-culture as
measured by sandwich Elisa demonstrated a significant increase in the ability of leptin and LPS
treated cells to activate T cells. This effect is more evident in the duo treatment of leptin and
LPS. A similar trend was noted on DC: T cell ratios of 1:20, 1:10 and 1:5, where duo treatment
leptin and LPS was most efficient at activating T cells, followed by LPS treated DC then leptin
treated DCs while media and chimera were nearly equivalently inefficient at activating T cells.
As expected the addition of Con A to non-treated DC also enhanced T cell activation although
not as efficiently as T cells in the presence of the duo leptin and LPS treated cells at a DC:T cell
ratio of 1:20. Minimal amounts of IL-2 were detected in 1:1 DC:T cell ratios (all treatments)
possibly because of low T cell numbers. A barely detectible or not detectible (ND) levels of IL-2
was found in the non-peptide containing wells with both treated and non-treated DC.
IFN-γ production also detected by Sandwich ELISA revealed a very similar trend to IL-2
results (Figure 4.2). Again leptin and LPS treated DC were much more efficient at activating T
cells in terms of IFN-γ production with the duo treatment the most efficient. However the
difference between the duo leptin and LPS treatment and LPS alone treatment was much more
marked in IFN-γ than it was in IL-2. Additionally the trend observed in IL-2 held true for IFN-γ
production for all DC:T cell ratios including 1:1 This means that the duo treatment was most
efficient at activating T cells followed by the LPS treatment, then the leptin treatment and finally
non-treated and OB-R-Fc treated. Once more Con A stimulation of T cells (positive control)
produced a robust INF-γ production but the duo leptin and LPS treatment was still approximately
1.5 times higher.
The final parameter assessed to analyze T cell activation was proliferation (figure 4.3). At
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the conclusion of the 72 hour co-culture 0.5 µCi tritated thymidine was added overnight). The
following morning cells were harvested and analyzed on a scintillation counter to assess
radioactivity. The results obtained for this study further supported cytokine data. Leptin
treatment significantly enhanced T cell activation in terms of proliferation in comparison to both
media and OB-R-Fc treatments. However it was not as efficient at activating T cells as the LPS
treated cells, but the most efficient DC at activating T cells were the duo treated cells. The
difference between the LPS and duo treated DCs was not as high as predicted but the trend
observed in both IL-2 and IFN-g remained. These effects were primarily observable in the DC:T
cell ratio of 1:20. All negative controls (media DC, DC + Ova, T cells and T cells + Ova) had
limited proliferation , while positive control Con A yielded highly proliferative T cells.

Conclusion
In conclusion exposure to leptin by DC prior to contact with T cells and a peptide visibly
enhance T cell activation. The results obtained are not a manifestation of the leptin acting
directly on the T cells to stimulate them and promote their activation since the treatments are
removed prior to co-culture. Additionally low detection of cytokines and radioactivity in
negative controls demonstrates that T cell activation was caused by DC and results obtained were
not due to DC proliferation or random T cell activation. It is clear that T cell are more activated
by DC treated with either leptin, LPS, or the duo leptin and LPS treatment as indicated by
proliferation, IL-2 and INF-γ production. Enhanced T cell activation by leptin treated cells with
and without LPS stimulus indicates that leptin treatment causes DC to become more potent
antigen presenting cells. We hypothesize that the increase in DC cell surface area and increased
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number/length/thickness of dendrites increases the number of T cells interacting with an
individual DC promoting an increased T cell response.
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Diagram 4.1 Summary of DC-T Cell Interactions – This diagram illustrates the basic
interactions required for T cells to become activated. Signal 1: MHC II DC present peptide to T
cells TCR. Signal 2: DC co-stimulatory receptors (CD80 and CD86) interact with their ligand
CD 28 on T cells to stimulate both DC and T cells , also DC CD40 receptor is simultaneously
stimulated by its ligand CD40L on T cells enhance DC activation. These interactions stabilize
the two cells and aid in cell signaling. Signal 3: A prolonged interaction occurs and that induces
transcription of the IL-2 gene to produce CD25 (IL-2 receptor), and promotes IL-2 production
100 fold (Immunology and immunotherapy approaches for prostate cancer E Elkord)
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Figure 4.1. Leptin Enhances DC Ability to Activate T Cell Hybridomas: DC were treated for
24 hours as indicated then co-cultured with T cell Hybridomas specific to ovalbumin. Peptide
was added at 500 µg/ml, co-culture was incubated at 37°C for 72 hours with 5% CO2.
Supernatants were collected and IL-2 production was determined by sandwich ELISA.
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Figure 4.2. Leptin Enhances DC Ability to Activate Primary T Cells in Terms of IFNγ Production - DC were treated for 24 hours as indicated then incubated for 4 hrs with
ovalbumin peptide at a concentration of 500 µg/ml. Primary CD4 enriched T cell specific to
ovalbumin were added at the indicated concentrations; co-culture was incubated at 37°C for 72
hours with 5% CO2. At the conclusion of this incubation supernatants were collected and INF-γ
production was determined by sandwich ELISA.
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Figure 4.3 Leptin Enhances DC Ability to Activate Primary T Cells in Terms of
Proliferation - DC were treated for 24 hours as indicated then incubated for 4 hrs with
ovalbumin peptide at a concentration of 500 µg/ml. Primary CD4 enriched T cell specific to
ovalbumin were added at the indicated concentrations; co-culture was incubated at 37°C for 72
hours with 5% CO2. At the 72 hr time point tritiated (3H) thymidine (0.5 µCi) was added to coculture overnight for 18 hours and proliferation was measured by incorporation of 3H
thymidine/radioactivity on a scintillation counter.

CHAPTER 5
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DISCUSSION

Leptin is secreted in direct correlation with the content of adipose tissue. Additionally,
leptin levels are not constant; rather, they range by sex and throughout the day with nutritional
state and activity level. Individuals who are overweight have a higher concentration of serum
bound and free circulating leptin in their blood stream (Sinha 1996). Leptin, the product of the
OB gene responsible for energy expenditure and appetite control, appears to affect the immune
system and increase the likelihood to develop autoimmune diseases as well as circulatory, renal,
and other chronic obesity related disease. The role that obesity and leptin play on autoimmunity
is unclear, little is known on their mechanisms of action and how leptin is involved.
Unfortunately autoimmune disorders have gradually increased over time, and there are limited
treatment options with high risks of infection or side effects. Chronic obesity related diseases are
also highly complicated to treat. The identification of the rapid rise of obesity has lead to it being
referred to as a worldwide epidemic, it is therefore necessary to understand the role of both
obesity and leptin on the immune system. DC play a critical role in the immune system because
activation of the adaptive immune system is primarily orchestrated through DC-T cell
interactions (Janeway 2005), it is therefore critical to understand the effect leptin has on DC.
The adipokine leptin may increase incidences of autoimmune diseases, by promoting a consistent
pro-inflammatory environment and enhancing macrophage, NK cells, B cells and T cell activity
as well as preventing production of regulatory T cells (Lam2006, Mattioli, 2005, De Rosa 2007).
This study seems to indicate that leptin plays an essential role in DC physiology and function.
Table 5.1 summarizes the results obtained in comparison to the non-treated (media) cells.
In this study we have determined three things. First, we have demonstrated that leptin
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promotes morphological changes and enhances pseudopodia formation particularly in the
presence of a maturation stimulator such as LPS. It also appears leptin induces an increase in
actin expression as well as promotes polymerization of actin, again particularly in the presence
of a stimulus. The increase in F actin may be due to effects on actin-modulating proteins that
allow for rapid assembly and disassembly of actin. It is therefore likely that the altered cellular
morphology is due to the shift from G-actin to F-actin and vice versa. Therefore the
morphological changes observed appear to be due to the actin re-organization as observed in
confocal studies, Western Blot analysis and indirect ELISA. In the absence/blocking of leptin
there is an obvious decrease in actin content as well as a decrease in F-actin. This may further
support that leptin is necessary for adequate DC morphology. A physiologically low and high
concentration of leptin were initially chosen for this study; however only the higher
concentration (160 ng/ml) was further studied due to its observed dramatic dendrite formation
and relevance to obesity (Figures 1.1, 1.2, 1.3 and Table 2.1).
Secondly, leptin alone or together with LPS promotes DC migration which is dependent
on cytoskeletal rearrangements. Leptin may possibly play a vital role in DC migration both in
immature and mature DC as observed by the presence or absence of LPS. It is apparent that
leptin plays a critical role in DC functionality, by promoting DC migration towards a
chemoattractant such as CCL19. This again is particularly true in the presence of LPS (Figure
3.1 and 3.2 Migration Assays). Leptin signaling is accomplished primarily by the JAK/STAT 3
pathway. Effects are transcriptionally observed within minutes of leptin addition (Data not
shown). Physiological/functional effects are observed within 24 hours, however as leptin
serum/media levels decrease the functionality also seems to decrease. This was clearly evident in
the migration assay, where the 24 hour treated DC migrated much more efficiently than the 48
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hour treated DC. Leptin may therefore affect migration in a dose dependent manner. CCL19 also
effected migration in a dose dependent manner with higher concentrations inducing greater
migration and lower concentrations producing limited migration. Similar trends were observed in
both 24 and 48 hour treatments but I believe that the decrease in migration at all concentrations
of CCL19 of the 48 hour treated DC is due to the decrease in available leptin in the media.
Further studies must be conducted to verify this theory. Leptin alone or together with LPS
promotes DC migration which is dependent on cytoskeletal rearrangements. We hypothesize
that the rapid turnover between G and F-actin is what allows for the enhanced migration. A
second possibility is an up-regulation of the chemokine receptor CCR7 and cell adhesion
molecules such as integrins. Further studies must be conducted to verify either of these theories.
The third and final observation established in this study is exposure to leptin by DC prior
to encountering peptide and T cells visibly enhances T cell activation as measured by T cell
proliferation, and cytokine (IL-2 and INF-γ) production. It is not clear however, how leptin
promotes DC to activate T cell. It may be due to increased surface area and lamellipodia
formations in the presence of leptin, allowing for an increase in the number of simultaneous T
cells interactions that therefore increase the likelihood of encountering a T cells specific to the
peptide it is carrying. Further studies must also be conducted to determine what exactly causes
this phenomenon.
The results obtained in this study demonstrate that leptin, particularly in the presence of a
stimulus such as LPS, enhances DC morphological changes and enhances functionality.
Furthermore this data suggest that leptin’s effect on DC is nearly immediate and that migration
and ability to activate T cells is in part dependent on leptin serum/media levels where the higher
concentrations exert a more potent effect. The combination of the described possible factors
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leptin plays in autoimmunity and the findings described in this study further support obesities’
link to autoimmune disorders. In these studies however, leptin was added or blocked post DC
differentiation and enrichment, not immediately upon initial bone marrow extraction; therefore it
is unclear what role leptin definitively plays on monocyte derived DC. In a physiological setting
cells are exposed to varying circulating leptin levels throughout the differentiation process, not
only post-differentiation; therefore a future study in which DC are provided leptin from start to
finish will be necessary to fully grasp leptin’s affect and role in the DC life cycles. In conclusion,
leptin is important in differentiated murine DC morphology and functionality because a sudden
increase in leptin levels in addition to a stimulus enhances DC function and induces
morphological changes. This leads us to conclude that leptin may play a role as an adjuvant, this
newly obtained knowledge could possibly aid in vaccine development targeting DCs and may
lead to newer, improved vaccines.
Although much more work is needed to completely understand leptin’s effect on the
immune system particularly DC, this study has slightly elucidated leptin’s affect on DC
morphology and functionality. Moreover, the addition of a high concentration of exogenous
leptin mimicked obesity and further studies may eventually help to elucidate its role on
autoimmune mechanisms. The results in this study now lead us to question how leptin effects
monocyte differentiation into DC. Future studies also include the assessment of the effect of
leptin on the molecular pathways of cytoskeletal re-arrangement, further analysis of DC-T cell
interaction to include interaction time, DC cytokine production and T cell and DC survival.
Ideally leptin’s affect should be monitored in-vivo, possibly in C57BL/6, Lep DB and Lep OB
mice and Diet Induced Obesity (DIO) mice.
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Table 5.1.

Table 5.1: Result Summary - This table is a summary of the results obtained in this study. It is
represented in comparison to media (non-treated cells).

CHAPTER 6
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Materials and Methods

Mice
Bone marrow stem cells were obtained from the long bones of C57Bl/6 mice upon reaching
adulthood (6-8 weeks of age). Primary CD4+ T cells were obtained from ovalbumin specific
TCR transgenic mice (strain C57BL/6-Tg425CBM/J). All strains of mice were either ordered
from Jackson Laboratory or bred on site at the University of Texas at El Paso Animal facility
from mice originating from Jackson Laboratory.

Medias
•

RPMI 1640 – RPMI 1640 (Invitrogen Rockville, MD) was used for Bone marrow (BM)
DC. It was supplemented with 1% Penicillin Streptomycin (pen/strep) (Invitrogen
Rockville, MD) and 10% Fetal Calf Serum (FCS) (Invitrogen Rockville, MD) and
cytokines IL-4, and GM-CSF (10ng/ml) (Peprotech Rocky Hill, NJ).

•

Iscove's complete media - Iscove's complete media was made for T cells from DMEM
or Iscove’s media (Invitrogen Rockville, MD) supplemented with 10% FBS, 1%
pen/strep, 1% sodium pyruvate (Gibco Langley, OK), 1% Glutamax (Gibco Langley OK)
and 0.4% β-mercaptoethanol (EM Science Lawrence, KS).

•

Minimal Esential Media - S-MEM media was used for T cell hybridomas (Invitrogen
Rockville, MD). It was enhanced with 1% Gentamycin, Pen/Strep, Sulfate (Gibco
Langley, OK) and β-Mercaptoethanol) and 10% FBS 6% tumor cocktail

•

Tumor cocktail - Tumor Cocktail was made of Dextrose (Fisher Houston, TX),
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Glutamine Essential and Non-Essential Amino Acids (VWR Brisbane, CA). The final
product was set at a pH of 7.0 with 10N NaOH, Sodium Pyruvate, Sodium Bicarbonate
(Sigma St. Louis, MO).
Cytokines, Peptides and Proteins
•

Interleukin-4 - Lyophilized Interleukin-4 (IL-4) (Peprotech Inc. Rocky Hill, NJ) was
reconstituted in Hanks Buffered Salt Solution (HBSS) (Thermo Scientific Logan, UT) for
a final concentration of 10µg/ml. Stock was then aliquoted out stored at -80 °C.

•

Granulocyte Colony Stimulating Factor - Lyophilized Granulocyte Colony Stimulating
Factor GM-CSF (Peprotech Inc. Rocky Hill, NJ) was reconstituted in Hanks Buffered
Salt Solution (HBSS) for a final concentration of 10µg/ml. Stock was then aliquoted out
stored at -80 °C.

•

Leptin - Murine recombinant leptin purchased from Alpha Diagnostic (San Antonio, TX)
was dissolved in 15 mM HCl and mixed with 7.5 mM NaOH. Stock solution was then
diluted in PBS, aliquoted out and stored at -20°C.

•

Recombinant Mouse MIP-3 β/CCL19 - Lypophilized Recombinant Mouse MIP3β/CCL19 was purchased from R & D Systems (Minneapolis, MN) and reconstituted in
sterile PBS at a final concentration of 50 µg/ml. CCL19 was then aliquoted out and
stored at -20°C.

•

OB-R-Fc – Lyophilized Recombinant Mouse Leptin R/Fc Chimera (R&D, Minneapolis,
MN) was reconstituted in sterile PBS to 200 µgml. It was aliquoted out and stored at 20°C

•

Ovalbumin Peptide (257-264) - Chicken ovalbumin fragment/Ovalbumin Peptide was
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purchased from Peptides International (Louisville, Kentucky) and diluted in Phosphate
Buffer System (PBS). It was then aliquoted out and stored at -20°C.
•

Lypopolysacharide – Lypopolysacharide (LPS) was purchased from Sigma Aldrich (St.
Louis MO); it was diluted in PBS, aliquoted out and stored at -20°C.

•

Concanavalin A - Concanavalin A (Con A) was purchased from (Sigma Aldrich St.
Louis MO). It was dissolved in PBS and aliquoted out at a concentration of 1 mg/ml.

Antibodies
•

Anti-Actin, Clone C4 - Anti Actin Ab (Millipore, Temecula. CA) was diluted (1:500 for
Western blot analysis or 0.1 µg/ml for indirect ELISA) in TBST with 5% Bovine Serum
Albumine (BSA) (Fisher, Fairly Lawn, NJ).

•

Goat anti-mouse IgG (H+L) – Goat anti- mouse IgG (KPL Baltimore, MD ) was diluted
(1:4000 For Western blot analysis or 5 µg/ml for Indirect Elisa) in 5% Non-Fat Dry milk
in TBS.

•

Rhodamine Phalloidin – Rhodamine Phalloidin (Cytoskeleton Inc. Denver, CO) was
reconstituted in 100% methanol to a stock solution of 14 µM. It was then aliquoted out
and stored in the dark at -20°C

•

Diamidino-2 penylindole dihydrochloride - Lyophilized Diamidino-2 penylindole
dihydrochloride (DAPI) (Fluka, Sigma-Aldrich, St. Louis, MO) was reconstituted I
10mMtris and 1 mM EDTA in milliQ at a pH of 8. It was stored at -20°C

Primary T Cells
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TCR transgenic mice were sacrificed at about 10 weeks of age. Mice were anesthetized with
Isoflurane USP (VWR Brisbane, CA) and sacrificed by cervical dislocation. The spleen and all
lymph nodes were isolated and placed in single cell suspension. T cells were enriched by positive
selection for CD4+ using IMAG purification system. Cell concentration were be determined by
trypan (Invitrogen, Rockville, MD) blue exclusion on a hemocytometer.

T cell hybridomas
T cell hybridomas specific for ovalbumin were generously donated by Dr. Philippa Marrack
from the National Jewish Medical and Research Center in Denver, CO and are currently
maintained in S-MEM media enhanced with tumor cocktail at 37°C with 5% CO2.

Bone Marrow Isolation to Generate DC
C57BL/6 mice were anesthetized with Isoflurane USP and sacrificed by cervical dislocation.
Skin and tissue on hind legs was removed and long bones placed in HBSS, they were then placed
in 70% EtOH (Fisher Houston, TX) to prevent contamination. Bone marrow was then flushed
from the bones and filtered through an autoclaved nylon mesh. RBCs were lysed using lysis
buffer and removed by centrifugation. Remaining cells were resuspended in complete RPMI
1640 with cytokines (GM-CSF, and IL-4) and incubated at 37°C with 5% CO2. On day 2
supernatant were removed and replaced with fresh complete media containing cytokines. On the
4th day, the cells were resuspended and split. Cells were enriched by positive selection for CDllc
using IMAG purification System on day 6. Finally cells were counted using trypan blue
exclusion on a hemocytometer and were ready for use.
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DC & T cell Enrichment
Purification was performed by positive selection using BD IMAG cell separation system (BD
Biosciences Pharminogen San Diego, CA). Cells were harvested, counted and placed in FACs
tubes at 107 cells per tube in 20% normal mouse serum (NMS) (Sigma. St Louis MO) and IMAG
buffer (composed of 0.5% BSA,(Sigma. St Louis MO) 2mM EDTA, 0.1% Sodium azide (Fisher
Houston, TX) in PBS ) then incubated on ice for 15 min. 1 µl of CD11c biotin antibody
(Dendritic Cells) or CD4 biotin antibody (CD4+ T cells) (Ab from BD Biosciences Pharminogen
San Diego, CA) was added and cells were again incubated on ice for 15 minutes. Contents were
washed with IMAG buffer then resuspended with streptavidin particles (20 µl for every 107
cells), tubes were then incubated for 30 minutes at 4°C. Upon completion of incubation cells
were added 450 µl of IMAG buffer and placed on the magnet for 6-8 minutes. Supernatants were
removed while on magnet and cells resuspended in 500 µl of IMAG buffer. They were then
placed on the magnet for 3 minutes and supernatants removed, this process was repeated 3 times
to ensure purity. Final population of cells was washed in IMAG buffer and resuspended in RPMI
media (DC) or Iscove’s Complete Media (T cells). Concentration of cells was finally determined
by trypan blue exclusion on a hemocytometer.

Flow Cytometry
Enrichment of cells was confirmed by flow cytometry to be >90%. Cells were placed in Flow
cytometry vials and analyzed by FC500 flow cytometer (Beckman Coulter, Miami, FL) using
CXP software. 10,000 viable cells per sample, were gated for lymphocytes (CD4+) or for DC
(CD11c) by a combination of forward and side scatter.
Treatment of Cells
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Enriched DC were placed in one the following treatment for 24 or 48 hours.
1.) 10 µg/mL LPS
2.) 1 mg/mL of OB-R-Fc
3.) Non-treated DC in RPMI 1640 media
4.) 16 ng/mL recombinant murine leptin
5.) 10 µg/mL LPS & 16 ng/mL recombinant murine leptin.
6.) 160 ng/mL recombinant murine leptin
7.) 10 µg/mL LPS & 160 ng/mL recombinant murine leptin
Non-treated cells functioned as a negative control. Bovine leptin in the media can bind to murine
leptin receptor therefore Ob-R chimera (Ob-R:Fc) treatment was added as a second control to
block bovine leptin found in the FBS of the media. This control will ensure that results obtained
are not due to leptin found in the media. Lipopolysaccharide (LPS) will function as a positive
control for DC maturation. A low (16ng/ml) and mid range (160 ng/ml) concentration of leptin
were chosen based on studies of Mexican Americans by Peltz (2007).

Light Microscopy
Enriched cells were placed in 4 or 8 chamber slides and allowed to rest for 24 hours. Treatments
were then added and cells were incubated for 24 hours with treatments as described above.
Images of cells were obtained with Micron 2004 software (by Westover Scientific ) using a
Fisher Scientific inverted light microscope at a magnification of 40x.

Confocal Microscopy
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Cells were treated as in light microscopy; but after 24 hour treatment slides were centrifuged at
500 rpm for 5 min and supernatant removed and replaced with 1% Paraformaldehyde (PFA) (
Fisher, Fair Lawn, NJ) for 10 minutes at room temperature. PFA was removed and slides were
washed out with PBS at room temperature, then permeabilization buffer was added (composed of
0.5% Triton X-100 in PBS From Sigma Aldrich, St. Louis, MO) for 5 minutes at room
temperature to allow staining of the cytoskeleton. Buffer was removed and slide re-washed with
PBS. F-actin was then stained with Rhodamine labeled Phalloidin (Cytoskeleton Inc Denver,
CO) 200 µl/chamber at 100 nM diluted in RPMI 1640 for 2 1/2 hrs at room temperature in the
dark. Slides were then washed with PBS at room temperature three times and the nucleus was
counterstained with 4',6-diamidino-2-phenylindole (DAPI) at 100nM in RPMI 1640 for 30
seconds at room temperature in the dark. Slides were washed one final time and Anti-fade
mounting medium (Fluka Biochemika Sigma Aldrich, St. Louis, MO ) was applied to the slide to
prevent loss of fluorescence. Cover slips were placed on slides and sealed with clear nail polish.
Images were analyzed with a Zeiss Scanning Confocal Microscope with Pascal Deconvulution
Time-Lapse Temp Control software.

Whole Cell Lysate Prepartation
DC were enriched and treated (4-8 million cells/treatment) as previously stated for 24 hours, they
were then harvested and centrifuged at 1200 RPM for 5 minutes and supernatants were
discarded. Cells were resuspended in 250 µl of 1x CPI (composed of 1 protease inhibitor cocktail
tablet [Roche Applied Sciences Mannheim Germany] diluted in 1x PBS) and transferred to
microcentrifuge tubes. Vials were continuously mixed for 15-20 minutes at 4ºC. Microcentrifuge
tubes were then centrifuged in an ultracentrifuge at 12 RCF at room temp for 10 minutes,
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supernatants were collected and transferred to new labeled centrifuge tubes and maintained at 80ºC until quantification by BCA kit was performed.

Quantification of Protein using BCA Protein Assay Kit
Whole cell lysates were obtain as previously mentioned, their concentration was determined
using a BCA protein Assay Kit from Pierce (Rockford, IL). Procedure was performed as
recommended by manufacturer. BSA standards were provided with kit and 8 doubling dilutions
were performed using PBS. Ten µl of each sample or standard were placed in duplicates on to a
96 well flat bottom tissue culture plate. 200 µl of working reagent was added to each well and
plate was incubated for 30 minutes at 37ºC. Plate was then removed from incubator and allowed
to reach room temperature. Protein concentration was determined using a spectrophotometer at
an absorbance of 562 nm.

F & G Actin Cell Lysates using Extration of Cytoskeletal and Soluble Protein Fractions
DC were treated for 24 hours as previously stated (4-8 million cells/treatment) and harvested into
15 ml conical tubes. They were then centrifuged at 1200 rpm for 5 min and supernatant was
discarded. Cells were resuspended in microtubule stabilization buffer (MSB) generously donated
by Dr. Sukla Roychowdhury (composed of 0.1M PIPES, 2M Glycerol, 5 mM MgCl2, 2mM
EGTA, 0.5% Trition X-100) to remove all traces of previous media. Tubes were then
recentrifuged and resuspended in 200 µl of MSB with 0.1M DTT (Biosource, Camarillo, CA),
1mM of Adenosine-5'-triphosphate (ATP) (Cytoskeleton Inc. Denver, CO) and 1 protease
inhibitor tablet. Tubes were incubated for 10 minutes at room temperature with periodic mixing,
then placed in a microfuge and centrifuged for 10 minutes at 12000 rpm. The supernatants were
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collected and placed into a clean tube labeled ST fraction and placed on ice. The remaining pellet
was resuspended in 200 µl of complete MSB and placed on ice for 15 minutes. Each vial was
then sonicated for 1 minute in intervals of three 20 seconds intervals. Finally pelleted samples
were centrifuged again for 12000 RPM for 10 minutes and supernatant was collected and placed
in a new centrifuge vial labeled MT fraction. ST and MT fractions were frozen at -80ºC until
quantification by Bradford Assay was performed.

Quantification of Protein using a Bradford Assay
BSA standards were made in PBS starting at 2 mg/ml; seven doubling dilutions were performed
to create a standard curve. 10 µl of standards or previously made samples were added to the
bottom of a clean cuvette (Bio-Rad, Hercules, CA) and 1 ml of Bradford Reagent was to each
sample adding one blank cuvette to account for background. Content of each vial was mixed by
inverting tub a few times and avoiding bubbles. Results were read on a spectrophotometer at 595
nm.

Western Blot
•

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) – 1.5 mm
thick glass plates were used to make 10% SDS gels, each composed of a separating and a
stacking portion. Each stacking gel was made by adding 4 mls of Milli Q water, 3.3 mls
of 30% Acrylamide, 2.5 mls of 1.5 M Tris in Milli Q at a pH of 8.8, 0.1 ml of 10% SDS,
0.1 ml of 10 % APS in Milli Q and 0.004 mls of TEMED (Sigma, St. Louis MO). The
stacking gel was composed of 4.1 ml of Milli Q, 1 ml of 30% Acrylamide, 0.75 ml of 1.0
M Tris at a pH of 6.8, 0.06 mls of 10%SDS, 0.06 mls of 10% APS and 0.006 ml of
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TEMED. SDS gel were placed in a running apparatis (Bio Trace, Pesacola, FL), the outer
chamber was filled with lower buffer while the inner chamber was filled with upper
buffer. Previously obtained quantified proteins were resuspended in 4X loading buffer at
3-10 µg/lane and loaded. One lane of the gel was reserved for Sigma’s ColorBurst
Electophoresis Marker (St. Louis, MO). Apparatus was connected to a Power Pac 200
(Bio-Rad, Hercules, CA) and run at 100 Volts for 60 minutes. The gel is then removed
from the glass for transfer onto Polyvinylidene Fluoride (PVDF) (Bio Trace, Pesacola,
FL) using a semidry technique with a Trans-Blot SD Semi-Dry transfer Cell (Bio-Rad,
Hercules, CA). Two filter papers were soaked in transfer buffer (48mM Tris, 39 mM
glycine, 20% methanol, 0.375mg/ml SDS in Milli Q)and placed on the anode of the
transfer apparatus. The PVDF was soaked in 100% methanol, then rinsed in Milli Q and
Transfer buffer, it is then placed on top of the filter paper and the gel is placed on top of
it. Lastly a second set of filter paper is placed on top of the gel and the pile was pressed
ensure adequate transfer. The apparatus is closed and attached to the Power Pac 200 (BioRad, Hercules, CA), it is run at 20 volts for 70 minutes.
•

Immunoblot - Membrane was removed from the transfer apparatus and placed in a
shaking container with 5% Carnation Non-Fat Dry Milk (Wal-Mart El Paso, TX) in TBS
(10mM Tris, 150 mM of NaCl in Milli Q water) for 1 hour. Membrane was then washed
three times by replacing milk with TBST (TBS + 0.05% Tween 20 [Fisher, Fair Lawn,
NJ]). Primary Antibody (1ºAb) (Anti-Actin) was diluted 1:500 in 5% BSA in TBST, It
was then placed in the container with the membrane shaking overnight at 4ºC. The
following morning the 1ºAb was removed and the membrane was washed 3 times in
TBST (10 minutes each wash). The secondary Ab (2ºAb) (Goat anti- mouse IgG) was
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diluted 1:4000 in 5% NF Dry Milk, it was incubated at room temperature for 1 hour with
continuous shaking. The 2 ºAb was discarded and the membrane was washed 3 times
with TBST and one final time with TBS. The membrane was placed protein side up onto
an X-Ray Cassette and Super Signal West Pico substrate (Pierce Rockford, IL) was added
directly to the membrane. CL-XPosure file (Thermo Scientific Rockford, IL) was placed
on top of the membrane for a varying amount of time and the image developed. Images
were finally analyzed using densitometry.

Densitometry
Western blot images were scanned into a computer as a JPEG file and Intensity of bands was
determined using Un-Scan-It Software and results were graphed on Prism Software.

Measurement of Actin by Indirect ELISA
Cell lysates were obtained as described; standards and lysates were diluted to 300 ng/ml or 500
ng/ml respectively in PBS. 50 µl were added to each well in a 96 well ELISA plate and
incubated overnight at 4ºC. Content was removed and plate was blocked with 200 µl/well of 5%
Carnation Non-Fat Dry milk in TBS for 10 minutes at room temperature. Milk was removed and
replaced with 100 µl/well of Anti-Actin, Clone C4 diluted to 0.1 µg/ml diluted in 5% BSA in
TBST, it was then covered and incubated at room temperature for 1 hour. Contents were again
removed and plate was washed 5 times with Elisa Wash Buffer. Secondary antibody (Goat antimouse IgG (H+L) was diluted in 5% Non-Fat Dry milk in TBS to 5 µg/ml (100 µl/well). The
plate was covered and incubated at room temperature for 1 hour. At the conclusion of this
incubation the plate was washed 7 times and 100 µl of chromogen was added to each well. The
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plate was incubated in the dark for 30 minutes, then the reaction was stopped with Stop solution
and the plate read at 450 nm in a spectrophotometer. Results were analyzed and graphed on
Prism Software and.

DC In-vitro Migration
In-vitro migration was assessed using 24 well 10 µm transwells. DC were treated as previously
stated for 24 and 48 hours. Cells were washed to remove traces of treatment and placed in RPMI
1640 in the upper chamber of a transwell at 400,000 cells/well. DC-specific chemokine (CCL19)
was placed at 200 ng.ml, 50 ng/ml and no CCL19 in the lower chamber. The plates were
incubated at 37ºC for 4 and 24 hours. Cells in the lower chamber were digitally photograph to
assess morphology and then harvested and counted by trypan blue exclusion to determine the
percentage of migrated DC. Finally Migrated DC were verified to be DC by flow cytometry
(CD11c +).

T Cell-DC Co-Cultures
Treated enriched primary DC and T cells either primary (CD4+ TCR Transgenic) or CD4+
Hybridoma, were placed in a 96 well round bottom tissue culture plate at 100,000 cells/well at
varying DC: T cell ratios (1:1, 1:5, 1:10, or 1:20). Ovalbuimin peptide was added to all wells at
500 µg/ml except for negative controls of each treatment set up at a DC:T cell ratio of 1:5. The
plate was then incubated at 37ºC with 5% CO2 for 72 hours. Supernatants were collected from
hybridoma plate for IL-2 production. Primary plate supernatants were analyzed for INF-γ
production and added [3H]-thymadine for future proliferation assay.
.In-Vitro T cell Activation
73

T cell activation was assessed using co-cultures of antigen specific T cells and treated BM-DC.
T cell hybridoma or primary CD4+ or CD8+ T cells from TCR transgenic mice were activated
by ovalbumin peptide-pulsed treated BM-DC (100,000 T cells to 20,000 BM-DC in a U-bottom
96-well plate). After 72 hours supernatants will be removed and T cell activation will be
measured by IL-2 or IFNγ production (to be assessed by Enzyme Linked Imunosorbent Assay
(ELISA). An additional assay will be conducted for the primary T cells; the plates will be pulsed
with 1 µCi of [3H]-thymadine for 18 hours (overnight pulse). Proliferation is determined as a
function of cell-associated radioactivity, which is counted using a scintillation beta counter.

Measurement of IFN-γγ
DC and Primary T cells were co-cultured as previously described, 72 hours after co-culture
supernatants were collected. Production of Interferon-Gamma by T cells in co-culture was
determined by R&D Systems Quantikine Mouse IFN-ã kit (Minneapolis, MN), Protocol was
followed as recommended by manufacturer. Standards were diluted in Calibrator Diluent RD5Y
starting at 6ng/ml with six doubling dilutions. 50 µl of Assay Diluent RD1-21 was added to all
wells, then 50 µl of sample, standard or control were added to each well, the plate was covered
and incubated for 2 hours at room temperature. Content was removed and plate was washed 5
times in wash buffer then 100 µl of conjugate was added to each well and plate was covered and
incubated at room temperature for 2 hours again. Contents were again discarded and plate was
washed 5 times. 100 µl of Substrate solution was added to each well and the plate was incubated
at room temperature in the dark for 30 minutes. Finally reaction was stopped by adding 100 µl of
stop solution to each well and results were read on a spectrophotometer at 450 nm with
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correction wavelength at 540 nm. Data was graphed using Prism Software.

IL-2 Detection
DC and T cells hybridomas were co-cultured; post 24 hour DC treatment. Supernatants were
collected 72 hours after co-culture and analyzed for IL-2 production by Biosource Invitrogen
cytokine and signaling IL-2 Sandwich Elisa kit (Camarillo, CA). Procedure was performed as
protocol indicated. Elisa plates were coated 100 µl/well with 1.25 µg/ml in coating buffer B and
incubated overnight at 4ºC. Plate was washed with washing buffer one time and then blocked for
one hour at room temperature with 300 µl/well of assay buffer. Standards (100 or 50 µl/well at 1
ng/ml), samples (100 or 50 µl/well) and detection Ab (50 µl/well at 0.01 µg/ml in assay buffer)
were added. Plate was covered and incubated for two hours at room temperature. The plate was
then washed 5 times with was buffer, 100 µl/well of Streptavidn-HRP (0.05 µg/ml in assay
buffer) was added to each well, it was then covered and incubated at room temperature for 30
min. At the conclusion of this incubation the plate was washed 5 times as before then 100 µl/well
of 3,3’5,5’-tetramethylbenzidine (TMB) substrate solution was added. The Plate was finaly
incubated for 30 min in the dark at room temperature and the reaction was stoped with 100 of
stop solution. Results were obtained on a spectrophotometer at an absorbance of 450 nm. Data
was then graphed on prism software and analyzed.

Statistical Analysis
Statistics were performed using Prism Graphing Software.
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